Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -3.15% and Operating profit at -12.43% over the last 5 years
2
Positive results in Mar 26
3
With ROE of 6.48%, it has a expensive valuation with a 1.50 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,452 Million (Small Cap)
34.00
NA
3.31%
-0.89
6.48%
1.68
Revenue and Profits:
Net Sales:
54 Million
(Quarterly Results - Jun 2026)
Net Profit:
13 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
18.21%
0%
18.21%
6 Months
-3.46%
0%
-3.46%
1 Year
-5.61%
0%
-5.61%
2 Years
40.55%
0%
40.55%
3 Years
-4.33%
0%
-4.33%
4 Years
0%
0%
0.0%
5 Years
-11.75%
0%
-11.75%
Zhejiang Xinguang Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-3.15%
EBIT Growth (5y)
-12.43%
EBIT to Interest (avg)
65.85
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.85
Sales to Capital Employed (avg)
0.32
Tax Ratio
14.76%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
56.14%
ROE (avg)
9.91%
Valuation key factors
Factor
Value
P/E Ratio
34
Industry P/E
Price to Book Value
2.21
EV to EBIT
20.49
EV to EBITDA
17.12
EV to Capital Employed
12.24
EV to Sales
4.36
PEG Ratio
4.50
Dividend Yield
2.51%
ROCE (Latest)
59.74%
ROE (Latest)
6.48%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
54.10
47.70
13.42%
Operating Profit (PBDIT) excl Other Income
15.10
7.50
101.33%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
13.30
7.40
79.73%
Operating Profit Margin (Excl OI)
215.30%
78.50%
13.68%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 13.42% vs 4.38% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 79.73% vs 174.07% in Jun 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Change(%)
Net Sales
88.50
0.00
NA
Operating Profit (PBDIT) excl Other Income
28.00
0.00
NA
Interest
0.00
0.00
NA
Exceptional Items
0.00
0.00
NA
Consolidate Net Profit
26.40
0.00
NA
Operating Profit Margin (Excl OI)
316.10%
0.00%
NA
USD in Million.
Net Sales
Not Applicable: The company has declared_date for only one period
Consolidated Net Profit
Not Applicable: The company has declared_date for only one period
About Zhejiang Xinguang Pharmaceutical Co., Ltd. 
Zhejiang Xinguang Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






